{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:03:43Z","timestamp":1776240223713,"version":"3.50.1"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,15]]},"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest malignancies with near-universal KRAS mutation. Although KRASG12D and KRASG12V are predominant, KRASG12R is also prevalent in PDAC yet rare in other KRAS-driven cancers such as lung and colorectal adenocarcinoma, suggesting pancreas-specific selective pressures. Unlike other KRAS mutants, KRASG12R fails to productively engage key nodes that amplify oncogenic output including wild-type (WT) RAS and PI3K signaling. Furthermore, KRASG12R-mutant PDAC has been shown to be more sensitive to MAPK\/ERK inhibition compared with other KRAS-mutant tumors. Three complementary studies now clarify how KRASG12R promotes PDAC growth and why this genotype may carry distinct therapeutic vulnerabilities. First, Burge and colleagues identify KRASG12R-independent PI3K maintenance driven by PTEN oxidation and broad PI3K isoform utilization, with nutrient limitation further enhancing PTEN oxidation. Second, in a separate study, Burge and colleagues develop KRASG12R mouse models and show that KRASG12R tumors exhibit reduced ERK\/MAPK transcription, collagen deposition, and metastasis. Third, Kamgar and colleagues demonstrate an impaired cross-talk of KRASG12R with WT RAS and stoichiometric dependencies that help explain heightened MEK inhibitor sensitivity, supported by clinical trials combining MEK and autophagy inhibition. Together, these articles reposition KRASG12R PDAC as a biologically constrained yet therapeutically exploitable subtype.<\/jats:p>\n                  <jats:p>See related article by Burge et al., p. 1854<\/jats:p>\n                  <jats:p>See related article by Burge et al., p. 1868<\/jats:p>\n                  <jats:p>See related article by Kamgar et al., p. 2042<\/jats:p>","DOI":"10.1158\/0008-5472.can-25-5676","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:23:35Z","timestamp":1776237815000},"page":"1817-1819","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Altered PI3K and ERK\/MAPK Signaling in KRASG12R-Driven Pancreatic Cancer Presents Opportunities for Precision Therapy"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5039-6750","authenticated-orcid":false,"given":"Herv\u00e9","family":"Tiriac","sequence":"first","affiliation":[{"name":"1Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California San Diego, San Diego, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1876-7675","authenticated-orcid":false,"given":"Dannielle D.","family":"Engle","sequence":"additional","affiliation":[{"name":"2Salk Institute for Biological Studies, La Jolla, California."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2026041503233260100_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026041503233260100_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","author":"Cancer Genome Atlas Research Network","year":"2017","journal-title":"Cancer Cell"},{"key":"2026041503233260100_bib3","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.ccell.2024.08.002","article-title":"Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer","volume":"42","author":"McIntyre","year":"2024","journal-title":"Cancer Cell"},{"key":"2026041503233260100_bib4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"2026041503233260100_bib5","doi-asserted-by":"crossref","first-page":"eadk0775","DOI":"10.1126\/science.adk0775","article-title":"Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers","volume":"384","author":"Klomp","year":"2024","journal-title":"Science"},{"key":"2026041503233260100_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/2159-8290.CD-19-1006","article-title":"Atypical KRAS(G12R) mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer","volume":"10","author":"Hobbs","year":"2020","journal-title":"Cancer Discov"},{"key":"2026041503233260100_bib7","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/0008-5472.CAN-24-4501","article-title":"PTEN oxidation promotes constitutive PI3K signaling and inducible macropinocytosis in pancreatic cancer","volume":"86","author":"Burge","year":"2026","journal-title":"Cancer Res"},{"key":"2026041503233260100_bib8","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1158\/2159-8290.CD-20-0442","article-title":"An in vivo kras allelic series reveals distinct phenotypes of common oncogenic variants","volume":"10","author":"Zafra","year":"2020","journal-title":"Cancer Discov"},{"key":"2026041503233260100_bib9","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1158\/0008-5472.CAN-25-2630","article-title":"KRAS G12R-mutant pancreatic cancer features limited ERK\/MAPK transcriptional activity and a distinctive tumor microenvironment","volume":"86","author":"Burge","year":"2026","journal-title":"Cancer Res"},{"key":"2026041503233260100_bib10","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1158\/0008-5472.CAN-25-0018","article-title":"Mutant and wild-type RAS cross-talk and stoichiometric deficiencies are determinants of sensitivity to targeted therapies in KRASG12R pancreatic ductal adenocarcinoma","volume":"86","author":"Kamgar","year":"2026","journal-title":"Cancer Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/8\/1817\/3764869\/can-25-5676.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/8\/1817\/3764869\/can-25-5676.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:23:37Z","timestamp":1776237817000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/8\/1817\/782631\/Altered-PI3K-and-ERK-MAPK-Signaling-in-KRASG12R"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":10,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4,15]]},"published-print":{"date-parts":[[2026,4,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-5676","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]}}}